SCHEMBL10200747

SCHEMBL10200747

[O-][n+]1ccc(OCc2ccccc2)c(I)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 3/20 0.46
FFAR1 O14842 1/20 0.43
MAPT P10636 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
MAPK1 P28482 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
HTR1A P08908 1/20 0.40
DRD2 P14416 1/20 0.40
LIPE Q05469 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
APP P05067 5/20 0.39
MAPK14 Q16539 2/20 0.38
LTA4H P09960 1/20 0.38
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA4 P22748 1/20 0.37
CA5A P35218 1/20 0.37
CA7 P43166 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL74678 0.75 MAPT (0.59) FFAR1MAPTL3MBTL1MAPK1TDP1
SCHEMBL14862955 0.75 LTA4H (0.38) GPR84L3MBTL1LTA4HSMN1; SMN2
SCHEMBL6992481 0.74 GPR84 (0.56) GPR84MAPTL3MBTL1MAPK1TDP1
SCHEMBL21266907 0.74 GPR84 (0.56) GPR84MAPTL3MBTL1MAPK1TDP1
Acetic Acid SCHEMBL27558041 0.74 RXRA (0.51) MAPTHTR1ANPC1RAB9AAPP
SCHEMBL557817 0.72 LMNA (0.57) MAPTL3MBTL1RAB9AAPPLTA4H
SCHEMBL5179465 0.71 GPR84 (0.53) GPR84MAPTL3MBTL1RAB9AAPP
SCHEMBL20755877 0.71 FFAR1 (0.57) FFAR1MAPTL3MBTL1MAPK1TDP1
SCHEMBL27656865 0.70 FFAR1 (0.49) FFAR1MAPTL3MBTL1MAPK1TDP1
SCHEMBL28843836 0.69 FFAR1 (0.59) FFAR1MAPTL3MBTL1MAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8569336-B2 Compounds for the treatment of inflammatory disorders TONG LING (US) 2013-10-29 US disclosed
US-20120015926-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TONG LING (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015926-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TNF, ADAMTS1, ADAMTS7 GPR84 3286/4885FFAR1 2427/4885MAPT 971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.